Document Detail

Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions.
MedLine Citation:
PMID:  12612470     Owner:  NLM     Status:  MEDLINE    
Mammography is the screening test of choice for breast cancer. Its low specificity leads to a large number of unnecessary biopsies. Scintimammography, with either Tc-sestamibi (MIBI) or Tc-anti-carcinoembryonic antigen (CEA) Fab', has been proposed as a non-invasive test to lower the high false positive rate of mammography in certain patients. The two agents have not been compared, nor has their combined application been evaluated. We performed a prospective, non-randomized, open-label, single-centre study of 32 women with clinically and mammographically suspected breast cancer [Breast Imaging Reporting and Data System (BI-RADS, American College of Radiology) 4 or 5]. All patients underwent Tc-MIBI and Tc-anti-CEA Fab' scintimammography, and the results were correlated with histopathology. Overall, the accuracies for MIBI and CEA scans were 90.3% (28/31) and 77.4% (24/31), respectively. The probability of disease after mammography was 0.939+/-0.081 (95% confidence interval, CI). The post-mammography probabilities after positive MIBI or CEA scan were 0.965 and 0.960, respectively, and after negative MIBI or CEA scan 0.750 and 0.875, respectively. None of the above differences is significant. The post-test probability when both scans were positive (irrespective of which was performed first) was 0.977. It can be concluded that there are indications that scintimammography with Tc-MIBI is superior to that with Tc-anti-CEA Fab' when these tests are used as screening tests for breast cancer. However, mammography remains the screening test of choice for highly suspicious clinically palpable breast lesions. In this group of patients, the application of scintimammography with either Tc-MIBI or Tc-anti-CEA Fab' (alone or in combination) offers no additional advantage.
E E Sanidas; S Koukouraki; A Velidaki; A Manios; E Stathopoulos; E De Bree; M Kafousi; E Kodogiannis; N Karkavitsas; D D Tsiftsis
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  24     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-03     Completed Date:  2003-10-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  England    
Other Details:
Languages:  eng     Pagination:  291-6     Citation Subset:  IM    
Department of Surgical Oncology, University Hospital of Herakleion, Medical School of Crete, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / diagnostic use*
Breast Neoplasms / pathology*,  radionuclide imaging*
Immunoglobulin Fab Fragments / diagnostic use*
Middle Aged
Neoplasm Staging
Organotechnetium Compounds / diagnostic use*
Radiopharmaceuticals / diagnostic use*
Receptor, erbB-2 / analysis
Receptors, Estrogen / analysis
Receptors, Progesterone / analysis
Reproducibility of Results
Sensitivity and Specificity
Technetium Tc 99m Sestamibi / diagnostic use*
Reg. No./Substance:
0/99mTc-anti-carcinoembryonic antigen antibody; 0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/Receptors, Estrogen; 0/Receptors, Progesterone; 109581-73-9/Technetium Tc 99m Sestamibi; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Melanoma patients evaluated by four different positron emission tomography reconstruction techniques...
Next Document:  Uptake of radiolabelled alpha-fetoprotein by experimental mammary adenocarcinoma and adenoma: in viv...